fulvestrant

FDA Drug Profile — CLIGAVYX, fulvestrant, FULVESTRANT, Fulvestrant

fulvestrant is listed in the FDA National Drug Code directory with 14 NDC codes, marketed under brand names including CLIGAVYX, fulvestrant, FULVESTRANT. Available dosage forms: injection, injection, solution, powder.

Drug details

Generic Name
fulvestrant
Brand Names
CLIGAVYX, fulvestrant, FULVESTRANT, Fulvestrant
Application Number
NDA210063
Sponsor
Avyxa Pharma, LLC
NDC Codes
14
Dosage Forms
INJECTION, INJECTION, SOLUTION, POWDER
Routes
INTRAMUSCULAR
Active Ingredients
FULVESTRANT

Indications and Usage

1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.